MK-0429

MK-0429 is an orally active, potent, selective small molecule pan-integrin antagonist originally developed by Merck & Co. It was first designed as a selective αvβ3 integrin inhibitor but was later found to potently inhibit multiple αv integrins including αvβ1, αvβ3, αvβ5, αvβ6, and αvβ8. The drug has demonstrated high affinity for these targets with nanomolar IC50 values[1][6][8]. Mechanistically, it blocks cell adhesion and signaling mediated by these integrins. Preclinical studies have shown that MK-0429 reduces melanoma metastasis in the lungs and suppresses tumor progression through antiangiogenic effects[2][3][7]. It also exhibits anti-fibrotic activity in models of lung injury and kidney fibrosis[6][8]. Clinically, it reached phase I trials for prostate cancer (with bone metastases) and osteoporosis but development was discontinued for prostate cancer[4][7]. Its therapeutic potential has been explored in oncology (melanoma metastasis prevention), fibrotic diseases (lung fibrosis), diabetic nephropathy (reducing proteinuria and kidney fibrosis), and bone turnover disease.